HighTower Advisors’s Arbutus Biopharma ABUS Stock Holding History

HighTower Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-19,065	Closed	-$82K	–	3284
2021 Q3	$82K	Buy	+19,065	New	+$63.5K	﹤0.01%	2870

Other funds holding ABUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

HighTower Advisors's ABUS Position: Q4 2021 in Review

HighTower Advisors sold out of Arbutus Biopharma (ABUS) in Q4 2021, closing a stake of 19,065 shares — an estimated $82K sold.

HighTower Advisors first reported a position in ABUS in Q3 2021 and held it in 1 quarter. The position peaked at $82K in Q3 2021. 122 funds tracked by Wall St. Rank hold ABUS as of Q4 2021.

HighTower Advisors reported no remaining Arbutus Biopharma position as of Q4 2021 after selling out during the quarter.
HighTower Advisors sold 19,065 Arbutus Biopharma shares in Q4 2021, an estimated $82K.
HighTower Advisors first reported a position in Arbutus Biopharma in Q3 2021 and held it in 1 quarter.
HighTower Advisors's Arbutus Biopharma position peaked at $82K in Q3 2021.
122 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2021.

Based on HighTower Advisors's 13F filing for Q4 2021, filed 10 Feb 2022.